文献速递眼底病与葡萄膜炎

叶黄素、玉米黄质和ω-3膳食补充对黄斑色素的影响:一项随机临床试验

Effect of Dietary Supplementation With Lutein, Zeaxanthin, and ω-3 on Macular Pigment: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

这项随机临床试验在法国两家大学医院纳入120名新生血管性年龄相关性黄斑变性(AMD)患者的一级后代,随机分入叶黄素加玉米黄质(L+Z)组或安慰剂组,每日补充6个月。结果显示两组间黄斑色素光密度(MPOD)变化无显著差异(0.036,95%CI -0.037至0.110,P=0.33),尽管L+Z组血浆叶黄素和玉米黄质水平显著升高。

要点

  • 在新生血管性AMD患者一级后代中,6个月叶黄素加玉米黄质补充未显著改变黄斑色素光密度。
  • L+Z组血浆叶黄素和玉米黄质水平在3个月和6个月时较安慰剂组显著升高。
  • 两组间MPOD变化差异为0.036(95%CI -0.037至0.110,P=0.33),未达统计学显著。

核心结论

  • 在LIMPIA试验中,新生血管性AMD患者的一级后代经6个月叶黄素和玉米黄质膳食补充后,用改良HRA和MPD-Visucam测量的MPOD未发生改变,尽管血浆水平显示持续暴露于叶黄素和玉米黄质。
  • 需要进一步研究以理解这些营养素在黄斑中的吸收和代谢机制、测量MPOD的最佳方法以及对患者的临床获益。

研究设计与样本

  • 本研究为随机临床试验(LIMPIA),治疗期6个月,随后6个月随访,分析基于意向性治疗原则。
  • 研究在法国两家大学医院(波尔多和第戎)进行,从2011年1月(首例参与者首次访视)至2013年2月(末例参与者末次访视),分析于2016年1月至11月进行。
  • 参与者为120名无任何视网膜眼病的个体,均为新生血管性AMD患者的一级后代。
  • 参与者按1:1比例随机接受每日2粒膳食补充胶囊或安慰剂,持续6个月。

主要发现

  • 共纳入120名参与者(每组60名),分析239只眼(叶黄素加玉米黄质[L+Z]组119只,安慰剂组120只)。
  • 参与者平均(标准差)年龄为56.7(6.6)岁,71.7%(n=86)为女性。
  • L+Z组在治疗3个月和6个月后血浆叶黄素和玉米黄质较安慰剂组显著升高。
  • 通过HRA在0.98°偏心度测量的MPOD在6个月与基线之间的组间变化差异为0.036(95%CI -0.037至0.110)(P=0.33)。

关键数值与推荐

  • 主要评估标准为补充6个月后MPOD的变化(双眼合格眼的值),使用改良MPD-Visucam 200(Carl Zeiss Meditec)和改良Heidelberg视网膜血管造影仪(Heidelberg Engineering)(HRA)在0.98°偏心度测量。
  • 统计分析对医院和危险因素进行了校正。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以理解这些营养素在黄斑中的吸收和代谢机制、测量MPOD的最佳方法以及对患者的临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Nutritional uptake of lutein, zeaxanthin, and ω-3 polyunsaturated fatty acids may increase macular pigment optical density (MPOD) and thereby protect against the development of age-related macular degeneration (AMD). OBJECTIVES: To estimate the efficiency of dietary supplementation containing lutein, zeaxanthin, ω-3 polyunsaturated fatty acids, and vitamins to increase the density of macular pigment in first-generation offspring of parents with neovascular AMD. DESIGN, SETTING, AND PARTICIPANTS: This study was a randomized clinical trial (Lutein Influence on Macula of Persons Issued From AMD Parents [LIMPIA]) with a 6-month treatment period, followed by a 6-month follow-up period. Analyses were based on the intent-to-treat principle. The setting was 2 university hospitals in France (at Bordeaux and Dijon) from January 2011 (first participant first visit) to February 2013 (last participant last visit). The analysis was conducted from January to November 2016. Participants were 120 individuals free of any retinal ocular disease. They were first-generation offspring of parents with neovascular AMD. INTERVENTIONS: Participants were randomized in a 1:1 ratio to receive either 2 daily dietary supplementation capsules or placebo for 6 months. MAIN OUTCOMES AND MEASURES: The primary assessment criterion was the evolution of MPOD after 6 months of supplementation (value of both eligible eyes) measured using the modified MPD-Visucam 200 (Carl Zeiss Meditec) and the modified Heidelberg Retina Angiograph (Heidelberg Engineering) (HRA) at 0.98° eccentricity. The statistical analysis was adjusted for hospital and for risk factors. RESULTS: Overall, 120 participants (60 in each group) were included, and 239 eyes were analyzed (119 in the lutein plus zeaxanthin [L + Z] group and 120 in the placebo group). Their mean (SD) age was 56.7 (6.6) years, and 71.7% (n = 86) were female. A statistically significant increase in plasma lutein and zeaxanthin was shown in the L + Z group after 3 months and 6 months of treatment compared with the placebo group. However, the difference between groups in the evolution of MPOD measured by HRA 0.98° eccentricity between 6 months and baseline was 0.036 (95% CI, -0.037 to 0.110) (P = .33). CONCLUSIONS AND RELEVANCE: Among first-generation offspring of parents with neovascular AMD in the LIMPIA trial, MPOD as measured with the modified HRA and the MPD-Visucam was not modified after 6 months of lutein and zeaxanthin dietary supplementation despite plasma levels showing continuous exposure to lutein and zeaxanthin. Further research is necessary to understand the mechanism of absorption and metabolism of these nutrients in the macula, the best way to measure MPOD, and the clinical benefit for the patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01269697.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Korobelnik JF, Rougier MB, Delyfer MN, et al. Effect of Dietary Supplementation With Lutein, Zeaxanthin, and ω-3 on Macular Pigment: A Randomized Clinical Trial. JAMA Ophthalmol. 2017. PMID: 28973076. doi:10.1001/jamaophthalmol.2017.3398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。